|
Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
Recent advances in our understanding of disease biology, biomarkers, new ...
Tibbitts J, Cavagnaro JA, Haller CA, Marafino B, Andrews PA, Sullivan JT,
http://dx.doi.org/10.1016/j.yrtph.2010.06.007
Regul Toxicol Pharmacol. 2010 Jun 15.
|
Assessing agonistic potential of a candidate therapeutic anti-IL21R antibody.
ABSTRACT: BACKGROUND: Selective neutralization of the IL21/IL21R signaling ...
Guo Y, Hill AA, Ramsey RC, Immermann FW, Corcoran C, Young D, Lavallie ER, Ryan M, Bechard T, Pfeifer R, Warner G, Bologna M, Bloom L, O'Toole M,
http://dx.doi.org/10.1186/1479-5876-8-50
J Transl Med. 2010 May 26;8:50.
|
Monoclonal antibody-induced cytokine-release syndrome.
Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and ...
Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E,
http://dx.doi.org/10.1586/eci.09.31
Expert Rev Clin Immunol. 2009 Sep;5(5):499-521.
|
PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases.
INTRODUCTION: CD44 is a cell adhesion molecule believed to play a critical ...
Runnels HA, Weber GL, Min J, Kudlacz EM, Zobel JF, Donovan CB, Thiede MA, Zhang J, Alpert RB, Salafia MA, Milici AJ, Burdette D, Bell RR, Beebe JS, Xu X,
http://dx.doi.org/10.1007/s12325-010-0010-0
Adv Ther. 2010 Mar;27(3):168-80. Epub 2010 Apr 26.
|
The safety and side effects of monoclonal antibodies.
Monoclonal antibodies (mAbs) are now established as targeted therapies for ...
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ,
http://dx.doi.org/10.1038/nrd3003
Nat Rev Drug Discov. 2010 Apr;9(4):325-38. Epub 2010 Mar 22.
|
|